Copy to clipboard 
Integra LifeSciences reported 3Q20 orthopedic revenue of USD $21.9 million, +5.1% vs. 3Q19. In the second quarter, the company noted that its orthopedics franchise showed the strongest improvement among all of its businesses as surgeons worked through backlogged procedures. That momentum carried into the third quarter as the backlog work completed.
Update, 1/4/21: Integra has completed the divestiture of its orthopedic business to Smith+Nephew, as the orthopedic industry increasingly consolidates toward large, fully diversified players.
“The orthopedics business generated about 6% of our total revenues, but accounted for 15% of our total inventory value and a similar percentage of total company SKUs. These metrics demonstrate the disproportionate amount of investment our orthopedics business has required without the benefits of scale. Relative lack of scale also impacted our sales productivity in orthopedics, which was significantly lower than our other businesses.” – Peter Arduini, Integra LifeSciences President & CEO
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q20 | 3Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $8.3 | $8.8 | ($0.4) | (4.9%) |
| Trauma | $13.6 | $12.1 | $1.5 | 12.4% |
| Total | $21.9 | $20.9 | $1.1 | 5.1% |
| 9m20 | 9m19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $20.8 | $27.0 | ($6.1) | (22.8%) |
| Trauma | $33.7 | $38.3 | ($4.6) | (12%) |
| Total | $54.6 | $65.3 | ($10.7) | (16.5%) |
Geographic Sales
| 3Q20 | 3Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $15.8 | $14.6 | $1.1 | 7.7% |
| OUS | $6.1 | $6.2 | ($0.1) | (1%) |
| EMEA | $2.7 | $2.7 | $0.0 | 0.5% |
| Asia Pacific | $2.4 | $2.3 | $0.1 | 3.5% |
| Rest of World | $1.0 | $1.2 | ($0.2) | (13.4%) |
| Total | $21.9 | $20.9 | $1.1 | 5.1% |
| 9m20 | 9m19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $38.6 | $46.3 | ($7.8) | (16.7%) |
| OUS | $16.0 | $19.0 | ($3.0) | (15.7%) |
| EMEA | $6.9 | $8.7 | ($1.8) | (20.5%) |
| Asia Pacific | $6.3 | $6.7 | ($0.4) | (6%) |
| Rest of World | $2.8 | $3.6 | ($0.8) | (22.2%) |
| Total | $54.6 | $65.3 | ($10.7) | (16.5%) |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $370.2 | |
| Cost of Sales | $134.8 | 37% |
| Selling and Admin | $150.1 | 41.2% |
| R & D | $19.5 | 5.3% |
| Other | $33.6 | 9.2% |
| Net Earnings | $32.3 | 8.9% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Integra LifeSciences reported 3Q20 orthopedic revenue of USD $21.9 million, +5.1% vs. 3Q19. In the second quarter, the company noted that its orthopedics franchise showed the strongest improvement among all of its businesses as surgeons worked through backlogged procedures. That momentum carried into the third quarter as the backlog work...
Integra LifeSciences reported 3Q20 orthopedic revenue of USD $21.9 million, +5.1% vs. 3Q19. In the second quarter, the company noted that its orthopedics franchise showed the strongest improvement among all of its businesses as surgeons worked through backlogged procedures. That momentum carried into the third quarter as the backlog work completed.
Update, 1/4/21: Integra has completed the divestiture of its orthopedic business to Smith+Nephew, as the orthopedic industry increasingly consolidates toward large, fully diversified players.
“The orthopedics business generated about 6% of our total revenues, but accounted for 15% of our total inventory value and a similar percentage of total company SKUs. These metrics demonstrate the disproportionate amount of investment our orthopedics business has required without the benefits of scale. Relative lack of scale also impacted our sales productivity in orthopedics, which was significantly lower than our other businesses.” – Peter Arduini, Integra LifeSciences President & CEO
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q20 | 3Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $8.3 | $8.8 | ($0.4) | (4.9%) |
| Trauma | $13.6 | $12.1 | $1.5 | 12.4% |
| Total | $21.9 | $20.9 | $1.1 | 5.1% |
| 9m20 | 9m19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement Extremities | $20.8 | $27.0 | ($6.1) | (22.8%) |
| Trauma | $33.7 | $38.3 | ($4.6) | (12%) |
| Total | $54.6 | $65.3 | ($10.7) | (16.5%) |
Geographic Sales
| 3Q20 | 3Q19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $15.8 | $14.6 | $1.1 | 7.7% |
| OUS | $6.1 | $6.2 | ($0.1) | (1%) |
| EMEA | $2.7 | $2.7 | $0.0 | 0.5% |
| Asia Pacific | $2.4 | $2.3 | $0.1 | 3.5% |
| Rest of World | $1.0 | $1.2 | ($0.2) | (13.4%) |
| Total | $21.9 | $20.9 | $1.1 | 5.1% |
| 9m20 | 9m19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $38.6 | $46.3 | ($7.8) | (16.7%) |
| OUS | $16.0 | $19.0 | ($3.0) | (15.7%) |
| EMEA | $6.9 | $8.7 | ($1.8) | (20.5%) |
| Asia Pacific | $6.3 | $6.7 | ($0.4) | (6%) |
| Rest of World | $2.8 | $3.6 | ($0.8) | (22.2%) |
| Total | $54.6 | $65.3 | ($10.7) | (16.5%) |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $370.2 | |
| Cost of Sales | $134.8 | 37% |
| Selling and Admin | $150.1 | 41.2% |
| R & D | $19.5 | 5.3% |
| Other | $33.6 | 9.2% |
| Net Earnings | $32.3 | 8.9% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
